Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 11/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6850975 | 0.75 | CRHR1 (0.48) | CRHR1GABRA2GABRB2 | |
| SCHEMBL6850979 | 0.69 | CRHR1 (0.50) | CRHR1GABRA2GABRB2 | |
| SCHEMBL6850852 | 0.58 | GABRA2 (0.39) | CRHR1GABRA2GABRB2 | |
| SCHEMBL4191079 | 0.55 | MEN1 (0.35) | — | |
| SCHEMBL27564981 | 0.55 | GABRA2 (0.48) | CRHR1GABRA2GABRB2 | |
| SCHEMBL7222445 | 0.55 | GABRG2 (0.34) | CRHR1GABRA2GABRB2 | |
| SCHEMBL7222451 | 0.55 | GABRG2 (0.34) | CRHR1GABRA2GABRB2 | |
| SCHEMBL7222448 | 0.55 | GABRG2 (0.34) | CRHR1GABRA2GABRB2 | |
| SCHEMBL15049985 | 0.54 | GABRA2 (0.43) | GABRA2GABRB2 | |
| SCHEMBL5600850 | 0.54 | CDK4 (0.51) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-05-06 | — | — | US | disclosed |
| US-6531475-B1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2003-03-11 | — | — | US | disclosed |
| US-6514982-B1 | Corticotropin releasing factor is believed to be the major physiological regulator of the basal and stress-release of adrenocorticotropic hormone, beta -endorphin, and other pro-opiomelanocortin-derived peptides from the pituitary | NEUROCRINE BIOSCIENCES, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1129091-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001087885-A1 | CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | CRHR1 1/4885GABRA2 147/4885GABRB2 171/4885 |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | CRHR1 1/4885GABRA2 147/4885GABRB2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.